B. E. Nilsson-Payant

SARS-CoV-2 hijacks p38β/MAPK11 to promote viral protein translation

This study identifies p38β as a critical host factor for SARS-CoV-2 replication and shows that inhibiting it reduces viral replication and cytokine production.

The host factor ANP32A is required for influenza A virus vRNA and cRNA synthesis

This study demonstrates that ANP32A is essential for both vRNA and cRNA synthesis in influenza A virus replication, challenging previous assumptions about its role.

Zinc-embedded fabrics inactivate SARS-CoV-2 and influenza A virus

This study shows that zinc-embedded PA66 fabrics absorb and inactivate SARS-CoV-2 and influenza A virus, with stable performance after multiple washes.

The FDA-approved drug Alectinib compromises SARS-CoV-2 nucleocapsid phosphorylation and inhibits viral infection in vitro

This study identifies Alectinib as an FDA-approved drug that inhibits SARS-CoV-2 nucleocapsid phosphorylation and viral replication in vitro by targeting host kinases.

Identification of Candidate COVID-19 Therapeutics using hPSC-derived Lung Organoids

This study uses hPSC-derived lung organoids to identify FDA-approved drugs that inhibit SARS-CoV-2 entry and reduce infection in a model of human COVID-19.

Human organ chip-enabled pipeline to rapidly repurpose therapeutics during viral pandemics

This paper demonstrates the use of human organ chips to rapidly repurpose therapeutics for viral pandemics, identifying amodiaquine as a potential treatment for SARS-CoV-2.

An inability to maintain the ribonucleoprotein genomic structure is responsible for host detection of negative-sense RNA viruses

The paper shows that limiting nucleoprotein (NP) in negative-sense RNA viruses leads to defective genomes and triggers host interferon responses, making NP a key antiviral target.